LLY Eli Lilly and Company Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
05:12
Sep 01
Sep 01
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings as a watchlist, not an explicit position.
LOW
02:14
Sep 01
Sep 01
Hold a global portfolio of strong US companies.
Instead of engaging in frequent sector rotation, investors should build a 'Best 11' global portfolio holding structurally sound US companies like NVIDIA, Alphabet, Eli Lilly (driven by Mounjaro), and Netflix, which offer strong long-term growth.
MED
11:20
Aug 31
Aug 31
Eli Lilly agrees to acquire Merida Biosciences for up to 2.88 billion dollars in cash to expand.
Eli Lilly agrees to acquire Merida Biosciences for up to 2.88 billion dollars in cash to expand its autoimmune and allergic disease portfolio.
10:47
Aug 31
Aug 31
Eli Lilly agrees to acquire Merida Biosciences for up to 2.875 billion dollars in cash.
02:14
Aug 29
Aug 29
NKTR v LLY legal catalyst flagged
Highlights NKTR v LLY legal case with trial set for September 8 and court-ordered mediation underway; no directional view stated.
LOW
15:13
Aug 28
Aug 28
The tweet details ongoing litigation and settlement dynamics between Nektar and Eli Lilly.
The tweet details ongoing litigation and settlement dynamics between Nektar and Eli Lilly without expressing a directional trading view on either stock.
LOW
15:12
Aug 28
Aug 28
Revenue increased 47% YoY, supported by a huge pipeline beyond weight loss, including immunity, oncology, and the newly approved Foundayo. Intensive efforts in AI drug design and a broad, expanding pipeline secure long-term, compounding revenue growth. Considered a "Mag 8" stock with a highly visible and bright future in next-generation pharma. Clinical trial failures, patent cliffs, or regulatory hurdles for experimental drugs.
HIGH
15:05
Aug 28
Aug 28
The FDA cleared Eli Lilly's Mounjaro to reduce cardiovascular risk in adults with type 2.
The FDA cleared Eli Lilly's Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes and established heart disease, according to a company statement on Friday.
11:01
Aug 28
Aug 28
Eli Lilly's diabetes drug Mounjaro receives FDA approval for heart disease indication.
Eli Lilly's diabetes drug Mounjaro receives FDA approval for heart disease indication, expanding its approved uses beyond diabetes.
23:42
Aug 27
Aug 27
A highly favored trillion-dollar drug company.
Eli Lilly is a highly favored trillion-dollar drug company that serves as a strong healthcare holding.
HIGH
21:00
Aug 26
Aug 26
Lilly has selected Veeva's Vault CRM, a major competitive win over Salesforce that solidifies Veeva's dominance in the top-tier of pharma.
HIGH
20:30
Aug 26
Aug 26
Agilent's pharma reshoring orders are arriving sooner than expected, with orders from five top-10 pharma companies already booked, suggesting the 'reshoring' narrative is converting to tangible revenue earlier than anticipated, with instruments and services being fully incremental. — Incremental demand from reshoring could provide a multi-year growth tailwind, especially for instrument sales, ahead of expectations.
HIGH
15:11
Aug 26
Aug 26
The author argues that strategic interest alone is usually sufficient for a deal to work out.
The author argues that strategic interest alone is usually sufficient for a deal to work out, responding to concerns about valuation differences without taking a directional position.
00:49
Aug 24
Aug 24
Eli Lilly is breaking out on fundamentals.
Eli Lilly is breaking out of a cup-and-handle pattern, supported by high-priced weight-loss drugs, and is leading the strong US biotech sector which acts as a safe haven when tech rests.
MED
20:17
Aug 21
Aug 21
Big Pharma faces oversight discount risk.
If Democrats take at least one chamber, they will use private-sector oversight as a second track, targeting companies with Trump ties and voter backlash. Big Pharma is directly in that Venn diagram, and Democrats are likely to call CEOs from companies like Novo Nordisk and Eli Lilly that signed drug pricing deals with the administration, so investors should put a discount into these stocks now.
HIGH
19:22
Aug 21
Aug 21
Lilly likely to settle to hide chats
Notes Eli Lilly is likely to pursue a settlement or revised deal with Nektar to prevent internal trial chats from becoming public.
MED
10:00
Aug 21
Aug 21
Eli Lilly chart looks great at highs.
In biotech, Eli Lilly just made an all-time high and its high-time-frame chart looks great.
LOW
10:00
Aug 20
Aug 20
AI breakthroughs make healthcare an attractive defensive rotation.
Healthcare innovation is a defensive sector that outperforms during tech rotations. Breakthroughs driven by AI adoption, such as Moderna's cancer trials and Eli Lilly's developments, make biotech and healthcare highly attractive areas for capital rotation.
MED
16:23
Aug 19
Aug 19
Eli Lilly breaks to new all-time high
Eli Lilly is called a monster and an easy long after printing an emphatic all-time high near $1,300 on the same bio/oncology rotation; Thread Guy specifically says he likes the LLY long.
MED
13:52
Aug 19
Aug 19
Eli Lilly adds $60B in market cap
Observes massive market cap addition for Eli Lilly during a strong biotech rally, no directional view.
LOW
12:14
Aug 19
Aug 19
Author prefers Eli Lilly for execution strength
Author prefers Eli Lilly over competitors based on stronger execution and pipeline developments.
MED
12:13
Aug 19
Aug 19
Eli Lilly defending as market leader
Observes Eli Lilly is now in a defensive position as the market leader in the space.
LOW
11:19
Aug 19
Aug 19
LLY chats bad; sanctions motion unlikely to survive
Comments that LLY's internal chats look damaging in the NKTR suit, sanctions reconsideration is unlikely to survive, and DOJ interest may expand exposure.
MED
17:24
Aug 17
Aug 17
Author holds long position in LLY
Author discloses an ongoing long position in LLY, intending to hold through sideways price action to avoid selling prematurely.
MED
13:25
Aug 17
Aug 17
OABI announces deal with LLY today
Notes OABI announced a deal with LLY today, no directional view on LLY.
LOW
11:27
Aug 15
Aug 15
The author compiles a thread of user-recommended non-AI tickers as a research watchlist.
The author compiles a thread of user-recommended non-AI tickers as a research watchlist, explicitly noting he cannot guarantee they are all non-AI, so these are indexed as watch rather than trade ideas.
LOW
16:40
Aug 14
Aug 14
LLY endorsed as top healthcare big-cap
Author affirms LLY as the best big-cap expression of the healthcare/biotech trade in response to a direct question; no catalyst or reasoning provided.
LOW
15:39
Aug 13
Aug 13
Upcoming GLP-3 approval will drive massive sales.
The company is on the verge of getting US approval for retatrutide (GLP-3), a highly effective fat-loss drug. They are aggressively shutting down the gray market, positioning the official drug to be one of the best-selling in history.
HIGH
10:20
Aug 13
Aug 13
Eli Lilly plans to seek US approval for a highly anticipated drug while facing widespread use.
Eli Lilly plans to seek US approval for a highly anticipated drug while facing widespread use of counterfeit versions that may complicate enforcement efforts.
05:08
Aug 13
Aug 13
Berenberg raises Eli Lilly's price target to 1,220 dollars from 1,135.
Berenberg raises Eli Lilly's price target to 1,220 dollars from 1,135, signaling an upgraded bullish outlook on the stock.
About LLY Analyst Coverage
Buzzberg tracks LLY (Eli Lilly and Company) across 63 sources. 109 bullish vs 6 bearish calls from 129 analysts. Sentiment: predominantly bullish (27%). 383 total trade ideas tracked. Past 7 days: 3 bullish, 7 watch. Latest voices: asklivermore, Jung Woo-chang, Bloomberg.